$1.70
3.14% today
Nasdaq, Feb 28, 05:19 pm CET
ISIN
US74017N1054
Symbol
PGEN
Sector
Industry

Precigen Inc Stock price

$1.75
+0.45 34.62% 1M
+0.60 52.17% 6M
+0.63 56.25% YTD
+0.13 8.02% 1Y
-0.50 22.22% 3Y
-1.97 52.96% 5Y
-37.46 95.54% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.06 3.31%
ISIN
US74017N1054
Symbol
PGEN
Sector
Industry

Key metrics

Market capitalization $512.52m
Enterprise Value $489.64m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 123.65
P/S ratio (TTM) P/S ratio 129.42
P/B ratio (TTM) P/B ratio 9.26
Revenue growth (TTM) Revenue growth -41.38%
Revenue (TTM) Revenue $3.96m
EBIT (operating result TTM) EBIT $-95.36m
Free Cash Flow (TTM) Free Cash Flow $-84.30m
Cash position $28.63m
EPS (TTM) EPS $-0.55
P/S forward 80.08
EV/Sales forward 76.51
Short interest 9.92%
Show more

Is Precigen Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Precigen Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Precigen Inc forecast:

3x Buy
75%
1x Sell
25%

Analyst Opinions

4 Analysts have issued a Precigen Inc forecast:

Buy
75%
Sell
25%

Financial data from Precigen Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
3.96 3.96
41% 41%
100%
- Direct Costs 7.99 7.99
18% 18%
202%
-4.03 -4.03
37% 37%
-102%
- Selling and Administrative Expenses 33 33
6% 6%
835%
- Research and Development Expense 53 53
14% 14%
1,333%
-90 -90
12% 12%
-2,270%
- Depreciation and Amortization 5.48 5.48
19% 19%
138%
EBIT (Operating Income) EBIT -95 -95
9% 9%
-2,408%
Net Profit -140 -140
64% 64%
-3,524%

In millions USD.

Don't miss a Thing! We will send you all news about Precigen Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Precigen Inc Stock News

Positive
Seeking Alpha
about 3 hours ago
BLA of PRGN-2012 for patients with Recurrent Respiratory Papillomatosis was accepted by FDA with a Priority Review date of August 27th of 2025. Marketing approval of PRGN-2012 for RRP would be huge because there is no FDA approved drugs for RRP. Also, there are an estimated 27,000 people in the United States who have it. PGEN is looking to form a strategic partnership or collaboration agreement...
Neutral
PRNewsWire
3 days ago
– Priority review reduces the BLA review timeline to 6-months and is granted to therapies that, if approved, would provide significant improvements in the treatment, diagnosis or prevention of serious conditions – – If approved, PRGN-2012 would be the first and only available FDA-approved therapy for eligible patients with RRP, a rare and devastating chronic disease for which the current standa...
Neutral
PRNewsWire
about 2 months ago
–   PRGN-2012 has potential to be first FDA-approved therapeutic for treatment of RRP, a rare and devastating chronic disease  – –   Company completed BLA submission for PRGN-2012 for treatment of adults with RRP  – –   Commercial readiness activities underway in anticipation of potential launch of PRGN-2012; Company started 2025 with approximately $100 million cash on-hand* with cash runway we...
More Precigen Inc News

Company Profile

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The firm focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. It operates through the following segments: PGEN Therapeutics, ActoBio, MBP Titan, Trans Ova and All Other. The PGEN Therapeutics segment is advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders and infectious diseases. The ActoBio segment involves in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The MBP Titan segment comprises of Methane Bioconversion Platform, and associated technologies, personnel, and facilities The Trans Ova segment includes provides advanced reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Head office United States
CEO Helen Sabzevari
Employees 202
Founded 1998
Website www.precigen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today